Cargando…

Preventing and Managing Toxicities of High-Dose Methotrexate

High-dose methotrexate (HDMTX), defined as a dose higher than 500 mg/m(2), is used to treat a range of adult and childhood cancers. Although HDMTX is safely administered to most patients, it can cause significant toxicity, including acute kidney injury (AKI) in 2%–12% of patients. Nephrotoxicity res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howard, Scott C., McCormick, John, Pui, Ching-Hon, Buddington, Randall K., Harvey, R. Donald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2016
Materias:	New Drug Development and Clinical Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153332/ https://www.ncbi.nlm.nih.gov/pubmed/27496039 http://dx.doi.org/10.1634/theoncologist.2015-0164

Ejemplares similares

Consensus Guideline for Use of Glucarpidase in Patients with High‐Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance
por: Ramsey, Laura B., et al.
Publicado: (2017)

Fixed Dosing of Monoclonal Antibodies in Oncology
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2017)

Thorough QT/QTc Evaluation of the Cardiac Safety of Secnidazole at Therapeutic and Supratherapeutic Doses in Healthy Individuals
por: Darpo, Borje, et al.
Publicado: (2017)

Discordance Between Child‐Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds
por: Elmeliegy, Mohamed, et al.
Publicado: (2020)

A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction
por: Gong, Jun, et al.
Publicado: (2019)

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations
por: Bardia, Aditya, et al.
Publicado: (2019)

A Phase I, First‐in‐Human Study of GSK2849330, an Anti‐HER3 Monoclonal Antibody, in HER3‐Expressing Solid Tumors
por: Gan, Hui K., et al.
Publicado: (2021)

Cardiotoxicity from Capecitabine Chemotherapy: Prospective Study of Incidence at Rest and During Physical Exercise
por: Lestuzzi, Chiara, et al.
Publicado: (2022)

A Long‐Term Extension Study of Bevacizumab in Patients With Solid Tumors
por: Oza, Amit M., et al.
Publicado: (2021)

Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma
por: DeMaria, Peter Joseph, et al.
Publicado: (2021)

Optimism Bias in the Design of Phase III Randomized Control Trials Evaluating PD-1/PD-L1 Targeting Monoclonal Antibodies
por: Al-Showbaki, Laith, et al.
Publicado: (2022)

Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
por: Ascione, Liliana, et al.
Publicado: (2023)

Influence of Meals and Glycemic Changes on QT Interval Dynamics
por: Cirincione, Brenda, et al.
Publicado: (2017)

Model‐Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion
por: Cirincione, Brenda, et al.
Publicado: (2017)

Tafenoquine succinate for malaria prevention
Publicado: (2019)

Elasomeran for prevention of COVID-19
Publicado: (2021)

Elasomeran/imelasomeran for prevention of COVID-19
Publicado: (2022)

Elasomeran+davesomeran for prevention of COVID-19
Publicado: (2023)

Tozinameran+riltozinameran and tozinameran+famtozinameran for prevention of COVID-19
Publicado: (2023)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

ChAdOx1-S vaccine for prevention of COVID-19
Publicado: (2021)

Recombinant varicella zoster virus glycoprotein E antigen vaccine for prevention of herpes zoster and postherpetic neuralgia
Publicado: (2021)

SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19
Publicado: (2022)

Personalized medicine: Striding from genes to medicines
por: Nair, Sunita R.
Publicado: (2010)

Diabetes mellitus: Exploring the challenges in the drug development process
por: Vaz, Julius A., et al.
Publicado: (2012)

Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t(last) (Common)
por: Fisher, Dennis, et al.
Publicado: (2015)

Effect of Study Design on Sample Size in Studies Intended to Evaluate Bioequivalence of Inhaled Short‐Acting β‐Agonist Formulations
por: Zeng, Yaohui, et al.
Publicado: (2017)

Estimation of the Power of the Food Effect on QTc to Show Assay Sensitivity
por: Ferber, Georg, et al.
Publicado: (2017)

The Cardiovascular Effects of a Meal: J‐T(peak) and T(peak)‐T(end) Assessment and Further Insights Into the Physiological Effects
por: Täubel, Jörg, et al.
Publicado: (2019)

Epitope Mapping: The First Step in Developing Epitope-Based Vaccines
por: Gershoni, Jonathan M., et al.
Publicado: (2012)

Biperiden Challenge Model in Healthy Elderly as Proof‐of‐Pharmacology Tool: A Randomized, Placebo‐Controlled Trial
por: Bakker, Charlotte, et al.
Publicado: (2021)

Intracranial Hemorrhage Following Oral Low-Dose Methotrexate After Multiple Toxicities Caused by High-Dose Methotrexate in Childhood Acute Lymphoblastic Leukemia
por: Xin, Ning, et al.
Publicado: (2019)

Association between high-dose methotrexate-induced toxicity and polymorphisms within methotrexate pathway genes in acute lymphoblastic leukemia
por: Xu, Meng, et al.
Publicado: (2022)

Early clinical indicators of acute kidney injury caused by administering high-dose methotrexate therapy to juvenile pigs
por: Buddington, Randal K., et al.
Publicado: (2023)

MYOCRISIN
Publicado: (1941)

Peramivir for influenza
Publicado: (2019)

Inotuzumab ozogamicin for acute lymphoblastic leukaemia
Publicado: (2019)

Guselkumab for plaque psoriasis
Publicado: (2019)

Durvalumab for urothelial carcinoma, non-small cell lung cancer
Publicado: (2019)

Cerliponase alfa for neuronal ceroid lipofuscinosis type 2 disease
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q3edht37ndscr1hh097m6v66gk